The Biostatistics Core serves as the focal point of biostatistics support for all the four Projects. The Core will provide regular advice on experimental design such as selection of end points, sample size and power, and optimal allocation of animal and dose. The Core handles data management of the four Projects in a secure central location and in a format consistent across Projects. The Core will perform expert statistical analyses that optimally answer the research question and represent state of the art practice. The Core will also facilitate data sharing with the general scientific community. The Core is staffed by two experienced biostatisticians who have daily working relationships with the Project investigators. Their offices are on the third floor of the Cancer Institute building, in close proximity to most of the Program Project investigators. The Core biostatisticians have been an integral part of the P01 application through working on experimental design, analyzing preliminary data and developing a detailed and tailored statistical plan for each Project. The Core biostatisticians have made a concerted effort to learn the clinical and biological science in this AML Program Project so as to provide the strongest statistical service. The Core has access to all needed software such as Microsoft Office 2007, SAS 9.3 and R. A dedicated Biostatistics Core provides easy and guaranteed access for the Program Project investigators and also allows biostatisticians to specialize in the Project areas, in terms of the scientific knowledge and in biostatistics expertise A dedicated Core provides timely and high quality biostatistics service as its focus. Cost-effectiveness is enhanced because the cumulative experience of all Core personnel and the combined facilities and resources are available to each of the four Projects. The Biostatistics Core also serves as an interface to the larger resources in biostatistics, data management and computing in the Department of Public Health Sciences. No additional computer hardware and software are needed.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Pennsylvania State University
United States
Zip Code
Shaw, Jeremy; Costa-Pinheiro, Pedro; Patterson, Logan et al. (2018) Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era. Adv Cancer Res 140:327-366
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59
Verma, Mohit K; Clemens, Julia; Burzenski, Lisa et al. (2017) A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo. J Immunol Methods 446:47-53
Olson, Kristine C; Kulling, Paige M; Olson, Thomas L et al. (2017) Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia. Cancer Biol Ther 18:290-303
Hengst, Jeremy A; Dick, Taryn E; Sharma, Arati et al. (2017) SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models. Cancer Transl Med 3:109-121
Morad, Samy A F; Davis, Traci S; MacDougall, Matthew R et al. (2017) Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer. Biochem Pharmacol 130:21-33
Doshi, Ushma A; Shaw, Jeremy; Fox, Todd E et al. (2017) STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia. Signal Transduct Target Ther 2:17051
Tan, Su-Fern; Pearson, Jennifer M; Feith, David J et al. (2017) The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia. Expert Opin Ther Targets 21:583-590
Linton, Samuel S; Sherwood, Samantha G; Drews, Kelly C et al. (2016) Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 8:208-22
Tan, Su-Fern; Liu, Xin; Fox, Todd E et al. (2016) Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget 7:83208-83222

Showing the most recent 10 out of 27 publications